Portfolio

We invest in digital health solutions that improve cancer patient journey, transform pharmaceutical R&D, and shift towards more patient centric healthcare.

In the area of disruptive therapeutic platforms we invest in solutions focused on gene and cell therapies.

Current investments

Novel ex vivo cell engineering platform for cell therapies
More info

Area of interest
Therapeutic platform

Stage
Development stage
More info
A start-up in digital therapy for pain and anxiety management
More info

Area of interest
Digital Health

Stage
Commercial stage
More info
AI powered digital pathology platform developing biomarkers for pharmaceutical development and precision oncology.
More info

Area of interest
Digital Health

Stage
Commercial stage
More info
Real-world patient experience platform for oncology enabling best treatment choices and new therapies
More info

Area of interest
Digital Health

Stage
Commercial stage
More info
In silico clinical trials platform. Uses
simulation to reduce the risk of R&D
decisions by predicting the clinical benefits
of new drugs in virtual clinical trials before
human trials begin
More info

Area of interest
Digital Health

Stage
Commercial stage
More info
High performance genomics and clinical big data management platform.
More info

Area of interest
Digital Health

Stage
Commercial, with global customer base
More info
Life-saving detection of sepsis
Host response signature for early identification of sepsis
More info

Area of interest
Digital Health

Stage
FDA approved test
More info
Signatures to guide cancer treatment.
Prognostic tests for cancer severity and recurrence.
Agendia website

Area of interest
Digital Health

Stage
On the market since 2004 (Europe) and 2008 (USA)
Agendia website
Life science platform helps translate breakthrough science into drugs by providing an incubator and resources for young biotechs
Eclosion website

Area of interest
Digital Health

Stage
4 portfolio companies, three in clinical stage, one IPO. One merger with a public company
Eclosion website

Past investments

A leader in the field of digital therapeutics
More info

Area of interest
Digital Health

Stage
Commercial stage
More info
Digital therapeutics and patient monitoring tools for oncology
More info

Area of interest
Digital Health

Stage
Commercial stage
More info
Point of care turn-key Dx platforms.
Instruments and cartridges for simple and rapid molecular diagnostics
Biocartis website

Area of interest
Digital Health

Stage
Idylla platform and first test launched in September 2014
IPO in April 2015
Biocartis website
Fusion of Effimune and the Euronext listed OSE Pharma. Immunomodulation in autoimmunity, transplantation, and immuno-oncology
OSE Immuno website

Area of interest
Digital Health

Stage
2 clinical stage programs, several preclinical programs
OSE Immuno website
PasNas research platform.
First-in-class drugs for precision treatment of MDR gram-negative infections.
ABAC Therapeutics website

Area of interest
Digital Health

Stage
Preclinical
ABAC Therapeutics website
New solutions for MDx pretreatment

Sample preparation technologies for molecular diagnostics
Spinomix website

Area of interest
Digital Health

Stage
Development phase of magnetic bead handling technology
Spinomix website
Developer of Colox test for blood-based Colorectal Cancer screening

Area of interest
Digital Health

Stage
Market entry in Switzerland through collaboration with Novigenix in 2014
Focused on active immunotherapy for autoimmune and inflammatory diseases

Initial public offering (IPO) in 2010
Neovacs website

Area of interest
Digital Health

Stage
Current vaccine development efforts are in Crohn’s disease, rheumatoid arthritis and lupus. In Phase IIb/III
Neovacs website